What is the recommended treatment and dosage for trimethoprim/sulfamethoxazole (Smz-tmp)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Trimethoprim-Sulfamethoxazole (TMP-SMX): Treatment and Dosing Recommendations

Primary Indication: PCP Prophylaxis in HIV

For HIV-infected adults and adolescents with CD4+ counts <200 cells/μL, TMP-SMX one double-strength tablet (800mg SMX/160mg TMP) daily is the preferred prophylactic regimen against Pneumocystis pneumonia. 1, 2

Prophylaxis Initiation Criteria

  • CD4+ count <200 cells/μL (strongest indication) 1, 2
  • History of oropharyngeal candidiasis (regardless of CD4 count) 1, 2
  • CD4+ percentage <14% 1, 2
  • History of AIDS-defining illness 1, 2
  • Consider prophylaxis at CD4+ 200-250 cells/μL when frequent monitoring is not feasible 1

Dosing Regimens for PCP Prophylaxis

Preferred regimen:

  • One double-strength tablet (800mg SMX/160mg TMP) once daily 1, 2, 3

Alternative effective regimens:

  • One single-strength tablet (400mg SMX/80mg TMP) once daily (better tolerated, equally effective) 1, 2
  • One double-strength tablet three times weekly 1, 2

Additional Protective Benefits

  • Provides cross-protection against toxoplasmosis at the double-strength daily dose 1, 2
  • Reduces common respiratory bacterial infections 1, 2

Treatment of Active PCP

For documented Pneumocystis pneumonia, administer TMP 15-20 mg/kg/day with SMX 75-100 mg/kg/day divided into 3-4 doses every 6 hours for 21 days. 1, 3, 4

Treatment Dosing by Weight (Upper Limit)

  • 18-35 lbs (8-16 kg): 1 tablet every 6 hours 3, 4
  • 53 lbs (24 kg): 1½ tablets every 6 hours 3, 4
  • 70 lbs (32 kg): 2 tablets or 1 double-strength tablet every 6 hours 3, 4
  • 88 lbs (40 kg): 2½ tablets every 6 hours 3, 4
  • 106 lbs (48 kg): 3 tablets or 1½ double-strength tablets every 6 hours 3, 4

For lower limit dosing (75 mg/kg SMX and 15 mg/kg TMP per 24 hours), administer 75% of the above doses. 3, 4

Route and Duration

  • Administer intravenously initially, infused over 1 hour 1
  • Switch to oral therapy once acute pneumonitis resolves in patients without malabsorption or diarrhea 1
  • Total treatment duration: 21 days 1, 3, 4

Urinary Tract Infections

For uncomplicated UTIs, administer one double-strength tablet every 12 hours for 10-14 days. 3, 4

Pediatric UTI Dosing (≥2 months old)

  • 40 mg/kg SMX and 8 mg/kg TMP per 24 hours divided every 12 hours for 10 days 3, 4
  • 22-44 lbs (10-20 kg): 1 tablet every 12 hours 3, 4
  • 66 lbs (30 kg): 1½ tablets every 12 hours 3, 4
  • 88 lbs (40 kg): 2 tablets or 1 double-strength tablet every 12 hours 3, 4

Note: TMP-SMX is no longer recommended as first-line empiric therapy for uncomplicated cystitis due to rising resistance rates; reserve for cases with known susceptibility. 1

Other Indications

Acute Exacerbations of Chronic Bronchitis

  • One double-strength tablet every 12 hours for 14 days 3, 4

Shigellosis

  • Same dosing as UTI but for only 5 days 3, 4

Traveler's Diarrhea

  • One double-strength tablet every 12 hours for 5 days 3, 4

Renal Dose Adjustment

Adjust dosing based on creatinine clearance to prevent toxicity: 3, 4

  • CrCl >30 mL/min: Standard dosing
  • CrCl 15-30 mL/min: Reduce dose by 50%
  • CrCl <15 mL/min: Do not use

Managing Adverse Reactions

For non-life-threatening reactions (mild rash, fever), continue TMP-SMX if clinically feasible rather than switching agents. 1, 2

Desensitization Protocol

  • After reaction resolution, reinstitute TMP-SMX with gradual dose escalation 1, 2
  • Up to 70% of patients tolerate reinstitution after desensitization 1, 2
  • Consider reduced dose or frequency during reintroduction 1

Absolute Contraindications

  • Urticarial rash or Stevens-Johnson syndrome: Permanently discontinue; do not rechallenge 1
  • Age <2 months: Contraindicated 3, 4

Common Adverse Effects in HIV Patients

  • Rash (including erythema multiforme) 1
  • Hematologic abnormalities (neutropenia, thrombocytopenia, anemia) 1
  • Hepatitis and renal disorders (interstitial nephritis) 1
  • Approximately 15% of HIV-infected children experience substantial adverse reactions (lower than adults) 1

Alternative Agents When TMP-SMX Cannot Be Used

If TMP-SMX is not tolerated for PCP prophylaxis, use dapsone 100mg daily as the preferred alternative. 1

Other alternatives include: 1

  • Dapsone plus pyrimethamine plus leucovorin (also protects against toxoplasmosis)
  • Aerosolized pentamidine via Respirgard II nebulizer
  • Atovaquone (expensive but effective)

For PCP treatment failure or intolerance, switch to pentamidine 4 mg/kg/day IV over 60-90 minutes. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Profilaxis con Trimetoprima-Sulfametoxazol en Pacientes con VIH

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.